EDM 1903 - New prostate cancer treatment 

12.07.2007
Gibson, Ian

That this House notes that prostate cancer is the most commonly diagnosed cancer in men and causes more than 10,000 deaths each year; laments the fact that men with prostate cancer report a significantly worse experience of treatment and care than patients with other cancers; welcomes the development in the UK of new treatments for men with prostate cancer, such as low dose rate (LDR) prostate brachytherapy, which offers patients improved quality of life after treatment compared with other treatment options; condemns the geographical variations which deny one in six men with prostate cancer in the UK access to this proven therapy; and calls upon the Government to support the work of the Prostate Brachytherapy Advisory Group to maximise patient access to LDR prostate brachytherapy across the whole of the United Kingdom.